{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T03:48:01Z","timestamp":1790394481708,"version":"4.1.0"},"reference-count":74,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2021,2,12]],"date-time":"2021-02-12T00:00:00Z","timestamp":1613088000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,2,12]],"date-time":"2021-02-12T00:00:00Z","timestamp":1613088000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Universit\u00e0 della Svizzera italiana"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Oncol Rep"],"published-print":{"date-parts":[[2021,3]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose of Review<\/jats:title>\n                <jats:p>Richter syndrome (RS) is an uncommon but aggressive evolution of chronic lymphocytic leukemia\/small lymphocytic lymphoma (CLL\/SLL). RS is an unmet clinical need in the field of CLL. Recent advances in understanding the biology of this condition provide the rationale for testing new therapeutic concepts in order to improve the outcome of patients developing RS, which is so far poor. In this review, we summarize disease characteristics and available therapeutic options for RS.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Recent Findings<\/jats:title>\n                <jats:p>Current regimens with novel agents in monotherapy have shown little impact on survival. Nevertheless, the better reported outcome for RS has been achieved with the combination of chemo-immunotherapy with a novel agent, confirming the synergistic effect of the approaches. Still, the frailty of this population may impose a less toxic management leaving most patients with no reasonable therapeutic option.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Summary<\/jats:title>\n                <jats:p>Treatment options for RS need to be further expanded. Preclinical models in current development may allow to explore actionable pathways and identify new drug targeted combinations.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s11912-020-01001-x","type":"journal-article","created":{"date-parts":[[2021,2,13]],"date-time":"2021-02-13T19:10:20Z","timestamp":1613243420000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["Richter Syndrome"],"prefix":"10.1007","volume":"23","author":[{"given":"Adalgisa","family":"Condoluci","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Davide","family":"Rossi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,2,12]]},"reference":[{"key":"1001_CR1","first-page":"285","volume":"4","author":"MN Richter","year":"1928","unstructured":"Richter MN. Generalized reticular cell sarcoma of lymph nodes associated with lymphatic leukemia. Am J Pathol. 1928;4:285\u201392.","journal-title":"Am J Pathol"},{"key":"1001_CR2","first-page":"180","volume-title":"World Health Organization Classification of Tumours, Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues","author":"HK M\u00fcller-Hermelink","year":"2008","unstructured":"M\u00fcller-Hermelink HK, Montserrat E, Catovsky D, Campo E, Harris NL, Stein H. Chronic lymphocytic leukemia\/small lymphocytic lymphoma. In: Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Vardiman JW, editors. World Health Organization Classification of Tumours, Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. Lyon: IARC; 2008. p. 180\u20132."},{"key":"1001_CR3","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1111\/bjh.12458","volume":"162","author":"SA Parikh","year":"2013","unstructured":"Parikh SA, Rabe KG, Call TG, Zent CS, Habermann TM, Ding W, et al. Diffuse large B-cell lymphoma (Richter syndrome) in patients with chronic lymphocytic leukaemia (CLL): a cohort study of newly diagnosed patients. Br J Haematol. 2013;162:774\u201382.","journal-title":"Br J Haematol"},{"key":"1001_CR4","doi-asserted-by":"publisher","first-page":"2673","DOI":"10.1182\/blood-2013-03-489518","volume":"122","author":"E Chigrinova","year":"2013","unstructured":"Chigrinova E, Rinaldi A, Kwee I, Rossi D, Rancoita PM, Strefford JC, et al. Two main genetic pathways lead to the transformation of chronic lymphocytic leukemia to Richter syndrome. Blood. 2013;122:2673\u2013782.","journal-title":"Blood."},{"key":"1001_CR5","doi-asserted-by":"publisher","first-page":"2273","DOI":"10.1084\/jem.20131448","volume":"210","author":"G Fabbri","year":"2013","unstructured":"Fabbri G, Khiabanian H, Holmes AB, Wang J, Messina M, Mullighan CG, et al. Genetic lesions associated with chronic lymphocytic leukemia transformation to Richter syndrome. J Exp Med. 2013;210:2273\u201388.","journal-title":"J Exp Med"},{"key":"1001_CR6","doi-asserted-by":"publisher","first-page":"3391","DOI":"10.1182\/blood-2010-09-302174","volume":"117","author":"D Rossi","year":"2011","unstructured":"Rossi D, Spina V, Deambrogi C, Rasi S, Laurenti L, Stamatopoulos K, et al. The genetics of Richter syndrome reveals disease heterogeneity and predicts survival after transformation. Blood. 2011;117:3391\u2013401.","journal-title":"Blood."},{"key":"1001_CR7","doi-asserted-by":"publisher","first-page":"1605","DOI":"10.1097\/PAS.0b013e31804bdaf8","volume":"31","author":"Z Mao","year":"2007","unstructured":"Mao Z, Quintanilla-Martinez L, Raffeld M, Richter M, Krugmann J, Burek C, et al. IgVH mutational status and clonality analysis of Richter\u2019s transformation. Am J Surg Pathol. 2007;31:1605\u201314.","journal-title":"Am J Surg Pathol"},{"key":"1001_CR8","doi-asserted-by":"publisher","first-page":"2343","DOI":"10.1200\/JCO.2005.05.0187","volume":"24","author":"AM Tsimberidou","year":"2006","unstructured":"Tsimberidou AM, O\u2019Brien S, Khouri I, Giles FJ, Kantarjian HM, Champlin R, et al. Clinical outcomes and prognostic factors in patients with Richter\u2019s syndrome treated with chemotherapy or chemoimmunotherapy with or without stem-cell transplantation. J Clin Oncol. 2006;24:2343\u201351.","journal-title":"J Clin Oncol"},{"key":"1001_CR9","doi-asserted-by":"publisher","first-page":"765","DOI":"10.3324\/haematol.2019.224121","volume":"105","author":"Y Wang","year":"2020","unstructured":". Wang Y, Tschautscher MA, Rabe KG, et al. Clinical characteristics and outcomes of Richter transformation: experience of 204 patients from a single center. Haematologica. 2020;105:765\u201373 A large single-institution cohort study defining the main characteristics of RS.","journal-title":"Haematologica"},{"key":"1001_CR10","doi-asserted-by":"publisher","first-page":"4415","DOI":"10.1158\/1078-0432.CCR-08-3266","volume":"15","author":"D Rossi","year":"2009","unstructured":"Rossi D, Spina V, Cerri M, Rasi S, Deambrogi C, De Paoli L, et al. Stereotyped B-cell receptor is an independent risk factor of chronic lymphocytic leukemia transformation to Richter syndrome. Clin Cancer Res. 2009;15:4415\u201322.","journal-title":"Clin Cancer Res"},{"key":"1001_CR11","doi-asserted-by":"publisher","first-page":"1066","DOI":"10.1111\/his.13024","volume":"69","author":"EJ Soilleux","year":"2016","unstructured":"Soilleux EJ, Wotherspoon A, Eyre TA, Clifford R, Cabes M, Schuh AH. Diagnostic dilemmas of high-grade transformation (Richter's syndrome) of chronic lymphocytic leukaemia: results of the phase II National Cancer Research Institute CHOP-OR clinical trial specialist haemato-pathology central review. Histopathology. 2016;69:1066\u201376.","journal-title":"Histopathology."},{"key":"1001_CR12","doi-asserted-by":"publisher","first-page":"1526","DOI":"10.3324\/haematol.2010.022277","volume":"95","author":"E Gin\u00e9","year":"2010","unstructured":"Gin\u00e9 E, Martinez A, Villamor N, L\u00f3pez-Guillermo A, Camos M, Martinez D, et al. Expanded and highly active proliferation centers identify a histological subtype of chronic lymphocytic leukemia (\"accelerated\" chronic lymphocytic leukemia) with aggressive clinical behavior. Haematologica. 2010;95:1526\u201333.","journal-title":"Haematologica."},{"key":"1001_CR13","doi-asserted-by":"publisher","unstructured":"Al-Sawaf O, Robrecht S, Bahlo J, et al. Richter transformation in chronic lymphocytic leukemia (CLL)-a pooled analysis of German CLL study group (GCLLSG) front line treatment trials. Leukemia. 2020. https:\/\/doi.org\/10.1038\/s41375-020-0797-xA large cohort of patients enrolled in clinical studies by the GCLLSG.","DOI":"10.1038\/s41375-020-0797-x"},{"key":"1001_CR14","first-page":"1405","volume":"91","author":"D Rossi","year":"2006","unstructured":"Rossi D, Berra E, Cerri M, Deambrogi C, Barbieri C, Franceschetti S, et al. Aberrant somatic hypermutation in transformation of follicular lymphoma and chronic lymphocytic leukemia to diffuse large B-cell lymphoma. Haematologica. 2006;91:1405\u20139.","journal-title":"Haematologica."},{"issue":"4","key":"1001_CR15","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1002\/ajh.23939","volume":"90","author":"SA Parikh","year":"2015","unstructured":"Parikh SA, Habermann TM, Chaffee KG, Call TG, Ding W, Leis JF, et al. Hodgkin transformation of chronic lymphocytic leukemia: incidence, outcomes, and comparison to de novo Hodgkin lymphoma. Am J Hematol. 2015;90(4):334\u20138.","journal-title":"Am J Hematol"},{"key":"1001_CR16","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1002\/ajh.24714","volume":"92","author":"FR Mauro","year":"2017","unstructured":"Mauro FR, Galieni P, Tedeschi A, Laurenti L, del Poeta G, Reda G, et al. Factors predicting survival in chronic lymphocytic leukemia patients developing Richter syndrome transformation into Hodgkin lymphoma. Am J Hematol. 2017;92:529\u201335.","journal-title":"Am J Hematol"},{"key":"1001_CR17","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.3109\/10428194.2012.723706","volume":"54","author":"L De Paoli","year":"2013","unstructured":"De Paoli L, Cerri M, Monti S, Rasi S, Spina V, Bruscaggin A, et al. MGA, a suppressor of MYC, is recurrently inactivated in high risk chronic lymphocytic leukemia. Leuk Lymphoma. 2013;54:1087\u201390.","journal-title":"Leuk Lymphoma."},{"issue":"23","key":"1001_CR18","doi-asserted-by":"publisher","first-page":"3580","DOI":"10.1182\/blood-2014-09-603217","volume":"125","author":"M Gounari","year":"2015","unstructured":"Gounari M, Ntoufa S, Apollonio B, Papakonstantinou N, Ponzoni M, Chu CC, et al. Excessive antigen reactivity may underlie the clinical aggressiveness of chronic lymphocytic leukemia stereotyped subset #8. Blood. 2015;125(23):3580\u20137.","journal-title":"Blood."},{"key":"1001_CR19","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1182\/blood-2011-09-379966","volume":"119","author":"D Rossi","year":"2012","unstructured":"Rossi D, Rasi S, Fabbri G, Spina V, Fangazio M, Forconi F, et al. Mutations of NOTCH1 are an independent predictor of survival in chronic lymphocytic leukemia. Blood. 2012;119:521\u20139.","journal-title":"Blood."},{"key":"1001_CR20","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1111\/j.1365-2141.2012.09155.x","volume":"158","author":"D Rossi","year":"2012","unstructured":"Rossi D, Rasi S, Spina V, Fangazio M, Monti S, Greco M, et al. Different impact of NOTCH1and SF3B1 mutations on the risk of chronic lymphocytic leukemia transformation to Richter syndrome. Br J Haematol. 2012;158:426\u20139.","journal-title":"Br J Haematol"},{"key":"1001_CR21","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.1038\/leu.2012.357","volume":"27","author":"N Villamor","year":"2013","unstructured":"Villamor N, Conde L, Mart\u00ednez-Trillos A, Cazorla M, Navarro A, Be\u00e0 S, et al. NOTCH1 mutations identify a genetic subgroup of chronic lymphocytic leukemia patients with high risk of transformation and poor outcome. Leukemia. 2013;27:1100\u20136.","journal-title":"Leukemia."},{"key":"1001_CR22","doi-asserted-by":"publisher","unstructured":"Abrisqueta P, Delgado J, Alcoceba M, et al. Clinical outcome and prognostic factors of patients with Richter syndrome: real-world study of the Spanish chronic lymphocytic leukemia study group (GELLC). Br J Haematol. 2020. https:\/\/doi.org\/10.1111\/bjh.16748A recent report of the characteristics of RS patients from the Spanish CLL Study Group (GELLC).","DOI":"10.1111\/bjh.16748"},{"key":"1001_CR23","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1182\/bloodadvances.2016003632","volume":"1","author":"S Kadri","year":"2017","unstructured":"Kadri S, Lee J, Fitzpatrick C, et al. Clonal evolution underlying leukemia progression and Richter transformation in patients with ibrutinib-relapsed CLL. Blood Adv. 2017;1:715\u201327 A recent molecular study reporting genomic profiles of serial samples from 9 patients with ibrutinib-relapsed disease, including 6 with Richter transformation. RS cells are described as clonal descendants of circulating leukemia cells progressively undergoing evolution and drifts. Interestingly, Authors report that transformed lymphoma cells in tissue may acquire a different BTK mutation from that in the CLL leukemia cells.","journal-title":"Blood Adv"},{"key":"1001_CR24","doi-asserted-by":"publisher","first-page":"3413","DOI":"10.1158\/0008-5472.CAN-17-4004","volume":"78","author":"T Vaisitti","year":"2018","unstructured":"Vaisitti T, Braggio E, Allan JN, et al. Novel Richter syndrome xenograft models to study genetic architecture, biology, and therapy responses. Cancer res. 2018;78:3413\u201320 In this paper are described the first two patient-derived xenograft models of Richter syndrome which represent ex vivo models to study biology of the disease and to test novel therapeutic strategies.","journal-title":"Cancer res"},{"key":"1001_CR25","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1200\/JCO.2016.70.2282","volume":"35","author":"JA Woyach","year":"2017","unstructured":"Woyach JA, Ruppert AS, Guinn D, Lehman A, Blachly JS, Lozanski A, et al. BTKC481S-mediated resistance to Ibrutinib in chronic lymphocytic leukemia. J Clin Oncol. 2017;35:1437\u201343.","journal-title":"J Clin Oncol"},{"key":"1001_CR26","first-page":"1267","volume":"47","author":"JF Bruzzi","year":"2006","unstructured":"Bruzzi JF, Macapinlac H, Tsimberidou AM, Truong MT, Keating MJ, Marom EM, et al. Detection of Richter's transformation of chronic lymphocytic leukemia by PET\/CT. J Nucl Med. 2006;47:1267\u201373.","journal-title":"J Nucl Med"},{"key":"1001_CR27","doi-asserted-by":"crossref","unstructured":"Gascoyne RD. XIV. The pathology of transformation of indolent B cell lymphomas. Hematol Oncol. 2015;33 Suppl 1:75\u201379.","DOI":"10.1002\/hon.2222"},{"issue":"18","key":"1001_CR28","doi-asserted-by":"publisher","first-page":"2783","DOI":"10.1182\/blood-2013-11-536169","volume":"123","author":"L Falchi","year":"2014","unstructured":"Falchi L, Keating MJ, Marom EM, Truong MT, Schlette EJ, Sargent RL, et al. Correlation between FDG\/PET, histology, characteristics, and survival in 332 patients with chronic lymphoid leukemia. Blood. 2014;123(18):2783\u201390.","journal-title":"Blood."},{"issue":"6","key":"1001_CR29","doi-asserted-by":"publisher","first-page":"1360","DOI":"10.1038\/leu.2015.21","volume":"29","author":"FR Mauro","year":"2015","unstructured":"Mauro FR, Chauvie S, Paoloni F, Biggi A, Cimino G, Rago A, et al. Diagnostic and prognostic role of PET\/CT in patients with chronic lymphocytic leukemia and progressive disease. Leukemia. 2015;29(6):1360\u20135.","journal-title":"Leukemia."},{"key":"1001_CR30","doi-asserted-by":"publisher","first-page":"1474","DOI":"10.3109\/10428194.2015.1099643","volume":"57","author":"AS Michallet","year":"2016","unstructured":"Michallet AS, Sesques P, Rabe KG, Itti E, Tordot J, Tychyj-Pinel C, et al. An 18F-FDG-PET maximum standardized uptake value\u2009>\u200910 represents a novel valid marker for discerning Richter's syndrome. Leuk Lymphoma. 2016;57:1474\u20137.","journal-title":"Leuk Lymphoma"},{"key":"1001_CR31","doi-asserted-by":"crossref","unstructured":"Mato AR, Wierda WG, Davids MS, et al. Analysis of PET-CT to identify Richter\u2019s transformation in 167 patients with disease progression following kinase inhibitor therapy. Blood. 2017;130(suppl 1). Abstract 834.","DOI":"10.1182\/blood.V130.Suppl_1.834.834"},{"key":"1001_CR32","doi-asserted-by":"publisher","first-page":"2343","DOI":"10.1200\/JCO.2005.05.0187","volume":"24","author":"A-M Tsimberidou","year":"2006","unstructured":"Tsimberidou A-M, O\u2019Brien S, Khouri I, et al. Clinical outcomes and prognostic factors in patients with Richter\u2019s syndrome treated with chemotherapy or chemoimmunotherapy with or without stem-cell transplantation. J Clin Oncol. 2006;24:2343\u201351.","journal-title":"J Clin Oncol"},{"issue":"12","key":"1001_CR33","doi-asserted-by":"publisher","first-page":"2268","DOI":"10.1002\/cncr.30596","volume":"123","author":"P Jain","year":"2017","unstructured":"Jain P, Thompson PA, Keating M, Estrov Z, Ferrajoli A, Jain N, et al. Longterm outcomes for patients with chronic lymphocytic leukemia who discontinue ibrutinib. Cancer. 2017;123(12):2268\u201373.","journal-title":"Cancer."},{"issue":"suppl 15","key":"1001_CR34","doi-asserted-by":"publisher","first-page":"6508","DOI":"10.1200\/jco.2011.29.15_suppl.6508","volume":"29","author":"JC Byrd","year":"2011","unstructured":"Byrd JC, Blum KA, Burger JA, Coutre SE, Sharman JP, Furman RR, et al. Activity and tolerability of the Bruton\u2019s tyrosine kinase (Btk) inhibitor PCI-32765 in patients with chronic lymphocytic leukemia\/small lymphocytic lymphoma (CLL\/SLL): interim results of a phase Ib\/II study [abstract]. J Clin Oncol. 2011;29(suppl 15):6508.","journal-title":"J Clin Oncol"},{"issue":"suppl 15","key":"1001_CR35","doi-asserted-by":"publisher","first-page":"7505","DOI":"10.1200\/JCO.2017.35.15_suppl.7505","volume":"35","author":"MS Davids","year":"2017","unstructured":"Davids MS, Huang Y, Rogers KA, Stern R, Brown JR, Thompson PA, et al. Richter\u2019s syndrome (RS) in patients with chronic lymphocytic leukemia (CLL) on novel agent therapy [abstract]. J Clin Oncol. 2017;35(suppl 15):7505.","journal-title":"J Clin Oncol"},{"key":"1001_CR36","doi-asserted-by":"publisher","first-page":"3362","DOI":"10.1182\/blood-2017-01-763003","volume":"129","author":"MA Anderson","year":"2017","unstructured":"Anderson MA, Tam C, Lew TE, Juneja S, Juneja M, Westerman D, et al. Clinicopathological features and outcomes of progression of CLL on the BCL2 inhibitor venetoclax. Blood. 2017;129:3362\u201370.","journal-title":"Blood."},{"key":"1001_CR37","doi-asserted-by":"publisher","first-page":"2199","DOI":"10.1182\/blood-2016-05-716977","volume":"128","author":"AR Mato","year":"2016","unstructured":"Mato AR, Nabhan C, Barr PM, Ujjani CS, Hill BT, Lamanna N, et al. Outcomes of CLL patients treated with sequential kinase inhibitor therapy: a real world experience. Blood. 2016;128:2199\u2013205.","journal-title":"Blood."},{"key":"1001_CR38","doi-asserted-by":"publisher","first-page":"E239","DOI":"10.1002\/ajh.23841","volume":"89","author":"P Langerbeins","year":"2014","unstructured":"Langerbeins P, Busch R, Anheier N, D\u00fcrig J, Bergmann M, Goebeler ME, et al. Poor efficacy and tolerability of R-CHOP in relapsed\/refractory chronic lymphocytic leukemia and Richter transformation. Am J Hematol. 2014;89:E239\u201343.","journal-title":"Am J Hematol"},{"key":"1001_CR39","doi-asserted-by":"publisher","first-page":"1749","DOI":"10.1200\/JCO.2009.25.3187","volume":"28","author":"WG Wierda","year":"2010","unstructured":"Wierda WG, Kipps TJ, Mayer J, Stilgenbauer S, Williams CD, Hellmann A, et al. Ofatumumab as single-agent CD20 immunotherapy in fludarabine-refractory chronic lymphocytic leukemia. J Clin Oncol. 2010;28:1749\u201355.","journal-title":"J Clin Oncol"},{"key":"1001_CR40","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1111\/bjh.14177","volume":"175","author":"TA Eyre","year":"2016","unstructured":"Eyre TA, Clifford R, Bloor A, Boyle L, Roberts C, Cabes M, et al. NCRI phase II study of CHOP in combination with ofatumumab in induction and maintenance in newly diagnosed Richter syndrome. Br J Haematol. 2016;175:43\u201354.","journal-title":"Br J Haematol"},{"key":"1001_CR41","doi-asserted-by":"publisher","first-page":"2951","DOI":"10.1182\/blood.V126.23.2951.2951","volume":"126","author":"KA Rogers","year":"2015","unstructured":"Rogers KA, Salem G, Stephens DM, Andritsos LA, Awan FT, Byrd JC, et al. A single-institution retrospective cohort study of patients treated with R-EPOCH for Richter's transformation of chronic lymphocytic leukemia. Blood. 2015;126:2951.","journal-title":"Blood."},{"key":"1001_CR42","doi-asserted-by":"publisher","first-page":"329","DOI":"10.3109\/10428190109064589","volume":"42","author":"BS Dabaja","year":"2001","unstructured":"Dabaja BS, O\u2019Brien SM, Kantarjian HM, Cortes JE, Thomas DA, Albitar M, et al. Fractionated cyclophosphamide, vincristine, liposomal daunorubicin (daunoXome), and dexamethasone (hyper-CVXD) regimen in Richter\u2019s syndrome. Leuk Lymphoma. 2001;42:329\u201337.","journal-title":"Leuk Lymphoma."},{"key":"1001_CR43","doi-asserted-by":"publisher","first-page":"1711","DOI":"10.1002\/cncr.11238","volume":"97","author":"AM Tsimberidou","year":"2003","unstructured":"Tsimberidou AM, Kantarjian HM, Cortes J, Thomas DA, Faderl S, Garcia-Manero G, et al. Fractionated cyclophosphamide, vincristine, liposomal daunorubicin, and dexamethasone plus rituximab and granulocytemacrophage- colony stimulating factor (GM-CSF) alternating with methotrexate and cytarabine plus rituximab and GMCSF in patients with Richter syndrome or fludarabine refractory chronic lymphocytic leukemia. Cancer. 2003;97:1711\u201320.","journal-title":"Cancer."},{"key":"1001_CR44","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1200\/JCO.2007.11.8513","volume":"26","author":"AM Tsimberidou","year":"2008","unstructured":"Tsimberidou AM, Wierda WG, Plunkett W, Kurzrock R, O\u2019Brien S, Wen S, et al. Phase I-II study of oxaliplatin, fludarabine, cytarabine, and rituximab combination therapy in patients with Richter\u2019s syndrome or fludarabine-refractory chronic lymphocytic leukemia. J Clin Oncol. 2008;26:196\u2013203.","journal-title":"J Clin Oncol"},{"key":"1001_CR45","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1016\/j.clml.2013.03.012","volume":"13","author":"AM Tsimberidou","year":"2013","unstructured":"Tsimberidou AM, Wierda WG, Wen S, Plunkett W, O'Brien S, Kipps TJ, et al. Phase I-II clinical trial of oxaliplatin, fludarabine, cytarabine, and rituximab therapy in aggressive relapsed\/refractory chronic lymphocytic leukemia or Richter syndrome. Clin Lymphoma Myeloma Leuk. 2013;13:568\u201374.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"1001_CR46","doi-asserted-by":"publisher","first-page":"3262","DOI":"10.1200\/JCO.2002.11.017","volume":"20","author":"TE Witzig","year":"2002","unstructured":"Witzig TE, Flinn IW, Gordon LI, Emmanouilides C, Czuczman MS, Saleh MN, et al. Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin\u2019s lymphoma. J Clin Oncol. 2002;20:3262\u20139.","journal-title":"J Clin Oncol"},{"key":"1001_CR47","doi-asserted-by":"publisher","first-page":"2195","DOI":"10.1002\/cncr.20252","volume":"100","author":"AM Tsimberidou","year":"2004","unstructured":"Tsimberidou AM, Murray JL, O\u2019Brien S, Wierda WG, Keating MJ. Yttrium-90 ibritumomab tiuxetan radioimmunotherapy in Richter syndrome. Cancer. 2004;100:2195\u2013200.","journal-title":"Cancer."},{"key":"1001_CR48","doi-asserted-by":"publisher","first-page":"2211","DOI":"10.1200\/JCO.2011.37.4108","volume":"30","author":"K Cwynarski","year":"2012","unstructured":"Cwynarski K, van Biezen A, de Wreede L, Stilgenbauer S, Bunjes D, Metzner B, et al. Autologous and allogeneic stem-cell transplantation for transformed chronic lymphocytic leukemia (Richter's syndrome): a retrospective analysis from the chronic lymphocytic leukemia subcommittee of the chronic leukemia working party and lymphoma working party of the European Group for Blood and Marrow Transplantation. J Clin Oncol. 2012;30:2211\u20137.","journal-title":"J Clin Oncol"},{"issue":"S1658\u20133876","key":"1001_CR49","first-page":"30097","volume":"20","author":"S Aulakh","year":"2020","unstructured":"Aulakh S, Reljic T, Yassine F, et al. Allogeneic hematopoietic cell transplantation is an effective treatment for patients with Richter syndrome: A systematic review and meta-analysis. Hematol Oncol Stem Cell Ther. 2020;20(S1658\u20133876):30097\u20132.","journal-title":"Hematol Oncol Stem Cell Ther"},{"key":"1001_CR50","doi-asserted-by":"publisher","first-page":"1294","DOI":"10.1002\/cncr.22121","volume":"107","author":"AM Tsimberidou","year":"2006","unstructured":"Tsimberidou AM, O'Brien S, Kantarjian HM, Koller C, Hagemeister FB, Fayad L, et al. Hodgkin transformation of chronic lymphocytic leukemia: the M. D Anderson Cancer Center experience. Cancer. 2006;107:1294\u2013302.","journal-title":"Cancer"},{"key":"1001_CR51","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1111\/j.1365-2141.2011.08907.x","volume":"156","author":"B Bockorny","year":"2012","unstructured":"Bockorny B, Codreanu I, Dasanu CA. Hodgkin lymphoma as Richter transformation in chronic lymphocytic leukaemia: a retrospective analysis of world literature. Br J Haematol. 2012;156:50\u201366.","journal-title":"Br J Haematol"},{"key":"1001_CR52","first-page":"785","volume":"34","author":"T Tadmor","year":"2014","unstructured":"Tadmor T, Shvidel L, Goldschmidt N, Ruchlemer R, Fineman R, Bairey O, et al. Hodgkin's variant of Richter transformation in chronic lymphocytic leukemia; a retrospective study from the Israeli CLL study group. Anticancer Res. 2014;34:785\u201390.","journal-title":"Anticancer Res"},{"key":"1001_CR53","doi-asserted-by":"publisher","first-page":"7614","DOI":"10.1200\/JCO.2005.02.7243","volume":"23","author":"WG Martin","year":"2005","unstructured":"Martin WG, Ristow KM, Habermann TM, Colgan JP, Witzig TE, Ansell SM. Bleomycin pulmonary toxicity has a negative impact on the outcome of patients with Hodgkin\u2019s lymphoma. J Clin Oncol. 2005;23:7614\u201320.","journal-title":"J Clin Oncol"},{"key":"1001_CR54","doi-asserted-by":"crossref","unstructured":"Johnson P, Federico M, Kirkwood A, Fossa A, Berkahn L, Carella A, et al. Adapted treatment guided by interim PET-CT scan in advanced Hodgkin\u2019s lymphoma. N Engl J Med. 2016 June 23;374:2419\u201329 A large prospective randomized trial to define whether the omission of bleomycin after negative interim PET-CT scan determines noninferior progression-free survival rate at 3 years, in comparison with patients continuing standard ABVD.","DOI":"10.1056\/NEJMoa1510093"},{"key":"1001_CR55","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1038\/nature10113","volume":"475","author":"XS Puente","year":"2011","unstructured":"Puente XS, Pinyol M, Quesada V, Conde L, Ord\u00f3\u00f1ez GR, Villamor N, et al. Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia. Nature. 2011;475:101\u20135.","journal-title":"Nature."},{"key":"1001_CR56","doi-asserted-by":"crossref","unstructured":"Kuruvilla J, Byrd JC, Flynn JM, Garzon R, Porcu P, Wagner-Johnston N, et al. The oral selective inhibitor of nuclear export (SINE) selinexor (KPT-330) demonstrates broad and durable clinical activity in relapsed\/refractory non Hodgkin\u2019s lymphoma (NHL). Blood. (ASH Annual Meeting Abstracts) 2014;124:396.","DOI":"10.1182\/blood.V124.21.396.396"},{"key":"1001_CR57","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1056\/NEJMoa1215637","volume":"369","author":"JC Byrd","year":"2013","unstructured":"Byrd JC, Furman RR, Coutre SE, Flinn IW, Burger JA, Blum KA, et al. Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. N Engl J Med. 2013;369:32\u201342.","journal-title":"N Engl J Med"},{"key":"1001_CR58","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1056\/NEJMoa1400376","volume":"371","author":"JC Byrd","year":"2014","unstructured":"Byrd JC, Brown JR, O\u2019Brien S, Barrientos KC, Kay NE, Reddy NM, et al. RESONATE Investigators Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. N Engl J Med. 2014;371:213\u201323.","journal-title":"N Engl J Med"},{"key":"1001_CR59","doi-asserted-by":"publisher","first-page":"1676","DOI":"10.1182\/blood-2014-12-610782","volume":"125","author":"M Tsang","year":"2015","unstructured":"Tsang M, Shanafelt TD, Call TG, Ding W, Chanan-Khan A, Leis JF, et al. The efficacy of ibrutinib in the treatment of Richter syndrome. Blood. 2015;125:1676\u20138.","journal-title":"Blood."},{"issue":"1","key":"1001_CR60","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2014.98","volume":"5","author":"S Giri","year":"2015","unstructured":"Giri S, Hahn A, Yaghmour G, Martin MG. Ibrutinib has some activity in Richter's syndrome. Blood Cancer J. 2015;5(1):e277.","journal-title":"Blood Cancer J"},{"issue":"2","key":"1001_CR61","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1159\/000477338","volume":"10","author":"S Master","year":"2017","unstructured":"Master S, Leary C, Takalkar A, Coltelingam J, Mansour R, Mills GM, et al. Successful treatment of Richter transformation with Ibrutinib in a patient with chronic lymphocytic leukemia following allogeneic hematopoietic stem cell transplant. Case Rep Oncol. 2017;10(2):534\u201341.","journal-title":"Case Rep Oncol"},{"key":"1001_CR62","doi-asserted-by":"publisher","first-page":"2260","DOI":"10.1182\/blood.V128.22.60.60","volume":"128","author":"P Hillmen","year":"2016","unstructured":"Hillmen P, Schuh A, Eyre TA, Pagel JM, Brown JR, Ghia P, et al. Acalabrutinib monotherapy in patients with Richter transformation from the phase 1\/2 ACE-CL-001 clinical study. Blood. 2016;128:2260.","journal-title":"Blood."},{"key":"1001_CR63","unstructured":"Blakemore S, Kohlhaas V, Al-Maarri M, et al. Active AKT signaling triggers CLL towards Richter's transformation via over-activation of NOTCH1. EHA 25 virtual congress 2020; abstract S154. Recent evidences assessing the role of the functional status of a potentially oncogenic signaling pathway in aggressive transformation of indolent lymphomas."},{"issue":"1","key":"1001_CR64","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1111\/bjh.15440","volume":"185","author":"A Visentin","year":"2019","unstructured":"Visentin A, Imbergamo S, Scomazzon E, et al. BCR kinase inhibitors, idelalisib and ibrutinib, are active and effective in Richter syndrome. Br J Haematol. 2019;185(1):193\u20137 A retrospective study reporting the results of potential new targeted treatment for RS.","journal-title":"Br J Haematol"},{"key":"1001_CR65","doi-asserted-by":"crossref","unstructured":"Davids MS, Roberts AW, Seymour JF, Pagel JM, Kahl BS, Wierda WG, et al. Phase I first-in-human study of venetoclax in patients with relapsed or refractory non-Hodgkin lymphoma. J Clin Oncol. 2017:JCO2016704320.","DOI":"10.1002\/hon.2438_67"},{"key":"1001_CR66","doi-asserted-by":"crossref","unstructured":"Davids MA, Rogers KA, Tyekucheva S, et al. A multicenter phase II study of venetoclax plus dose-adjusted R-EPOCH (VR-EPOCH) for Richter\u2019s syndrome. J Clin Oncol 38: 2020 (suppl; abstr 8004). Recent encouraging data about the new combination of venetoclax with R-EPOCH for patients with DLBCL variant RS.","DOI":"10.1200\/JCO.2020.38.15_suppl.8004"},{"issue":"26","key":"1001_CR67","doi-asserted-by":"publisher","first-page":"3419","DOI":"10.1182\/blood-2017-02-765685","volume":"129","author":"W Ding","year":"2017","unstructured":"Ding W, LaPlant BR, Call TG, Parikh SA, Leis JF, He R, et al. Pembrolizumab in patients with CLL and Richter transformation or with relapsed CLL. Blood. 2017;129(26):3419\u201327.","journal-title":"Blood."},{"key":"1001_CR68","doi-asserted-by":"publisher","first-page":"E966","DOI":"10.1073\/pnas.1500712112","volume":"112","author":"I Sagiv-Barfi","year":"2015","unstructured":"Sagiv-Barfi I, Kohrt HE, Czerwinski DK, Ng PP, Chang BY, Levy R. Therapeutic antitumor immunity by checkpoint blockade is enhanced by ibrutinib, an inhibitor of both BTK and ITK. Proc Natl Acad Sci U S A. 2015;112:E966\u201372.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"2","key":"1001_CR69","doi-asserted-by":"publisher","first-page":"e67","DOI":"10.1016\/S2352-3026(18)30217-5","volume":"6","author":"A Younes","year":"2019","unstructured":"Younes A, Brody J, Carpio C, et al. Safety and activity of ibrutinib in combination with nivolumab in patients with relapsed non-Hodgkin lymphoma or chronic lymphocytic leukaemia: a phase 1\/2a study. Lancet Haematol. 2019;6(2):e67\u201378 A phase 1\/2a study was designed to assess the safety and efficacy of ibrutinib in combination with nivolumab in patients with relapsed or refractory hematological malignancies including high-risk CLL\/SLL, follicular lymphoma, diffuse large B-cell lymphoma, and Richter\u2019s transformation. Overall response was seen in the Richter\u2019s transformation cohort (13 [65%] of 20 patients), with two CRs and 11 PRs. The median duration of response was 6.9 months (1.4\u2013NE) for the Richter\u2019s transformation cohort.","journal-title":"Lancet Haematol"},{"key":"1001_CR70","doi-asserted-by":"publisher","unstructured":"Leiming X, Qian C, Qiao L, Tan L, Yi W, Yangyi B. The clinical study on CD19-directed chimeric antigen receptor-modified T cells in patient with Richter Syndrome. https:\/\/doi.org\/10.1158\/1538-7445.AM2017-CT041.","DOI":"10.1158\/1538-7445.AM2017-CT041"},{"key":"1001_CR71","doi-asserted-by":"publisher","first-page":"5660","DOI":"10.1182\/blood.V124.21.5660.5660","volume":"124","author":"A Evans","year":"2014","unstructured":"Evans A, Burack R, Rothberg PG, Porter D, Liesveld JL. Evolution to Plasmablastic lymphoma (PBL) after CAR-T cell therapy in a case of SLL\/CLL with Richter\u2019s transformation. Blood. 2014;124:5660.","journal-title":"Blood."},{"key":"1001_CR72","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1182\/blood-2015-03-567388","volume":"126","author":"F Forconi","year":"2015","unstructured":"Forconi F, Moss P. Perturbation of the normal immune system in patients with CLL. Blood. 2015 Jul 30;126:573\u201381.","journal-title":"Blood."},{"key":"1001_CR73","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1038\/nri3862","volume":"15","author":"EJ Wherry","year":"2015","unstructured":"Wherry EJ, Kurachi M. Molecular and cellular insights into T cell exhaustion. Nat Rev Immunol. 2015;15:486\u201399.","journal-title":"Nat Rev Immunol"},{"key":"1001_CR74","doi-asserted-by":"publisher","first-page":"1650","DOI":"10.1182\/blood.2019002936","volume":"135","author":"J Gauthier","year":"2020","unstructured":"Gauthier J, Hirayama AV, Purushe J, et al. Feasibility and efficacy of CD19-targeted CAR T cells with concurrent ibrutinib for CLL after ibrutinib failure. Blood. 2020;135:1650\u201360 Recent data from a pilot study to evaluate the safety and feasibility of administering ibrutinib concurrently with CD19 CAR T-cell immunotherapy.","journal-title":"Blood"}],"container-title":["Current Oncology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11912-020-01001-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11912-020-01001-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11912-020-01001-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,29]],"date-time":"2023-01-29T07:23:19Z","timestamp":1674976999000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11912-020-01001-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,12]]},"references-count":74,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,3]]}},"alternative-id":["1001"],"URL":"https:\/\/doi.org\/10.1007\/s11912-020-01001-x","relation":{},"ISSN":["1523-3790","1534-6269"],"issn-type":[{"value":"1523-3790","type":"print"},{"value":"1534-6269","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,12]]},"assertion":[{"value":"17 December 2020","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 February 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"Neither of the authors has any potential conflicts of interest to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}}],"article-number":"26"}}